SahmAdrangi is an Iranian-born Canadian, founder and the Chief Investment Officer of Kerrisdale Capital Management. SahmAdrangi is a holder of Bachelors of Arts in Economics from the Yale University. At the University, he wrote cavalcades for the campus newspaper which shows his subliminal progression from lefty rabble-rouser.
Before finding his firm, he was an investment analyst at Longacre Fund, which is a private investment partnership. In the firm, he conducted investment analysis and research for both the credit fund and equity fund. He has also worked at Chanin Capital Part in the bankruptcy restructuring group where he gave advice to creditors. His work included representing bondholder committees, bank debt holders, preferred equity committees and creditors of bankrupt companies. He has also worked at Leverage Finance group of Deutsche Bank where his job was to syndicate and structure high yield bonds and non-investment grade bank debt, by buy-out financing, exit financing, and debt refinancing.
Sahm at Kerrisdale Capital Management
In Kerrisdale Capital Management, he has been in charge of all developmental operations. The company was launched with under $1 million but it currently manages $150 million. He is best known for publishing and short-selling research. Besides publishing research, he has been an activist in many investments including Lindsay corporation management. He has been a speaker at several conferences, which includes the Sohn Conference, the distressed debt investing conference, the value investing conference and traders for a cause. He got famous when he first exposed fraudulent Chinese companies, subsuming China-biotics, Lihua international, China Marine Food Group and many others. He has appeared in various interviews on Bloomberg and CNBC where he’s been headlined in major publications including, Washington Post, Wall Street Journal, New York Times, among others.
Adrangi is a fairly recent convert to dog-eat-dog capitalism. While his firm shares research on a wide variety of industries and companies, recently, he has focused the firm’s evolvement on specific sectors where it has refined expertise. One area of focus has been the Biotechnology sector and it has published research on development stage companies which includes Zafgen, Therapeutics, Bavarian Nordic and plentiful others.